Breaking News

Financial Reports: Teva

By Gil Roth | February 6, 2014

Generic exclusivity boosts 4Q revenues

Teva 4Q13

4Q Revenues: $5.4 billion (+3%)

4Q Earnings: $380 million (+19%)

FY Revenues: $20.3 billion (flat)

FY Earnings: $1.3 billion (-34%)

Comments: Generic revenues were up 1% in 4Q to $2.7 billion (including $163 million in third-party API sales), with U.S. revenues growing 14% to $1.2 billion, driven by exclusive launches of generics for Niaspan, Temodar, Cymbalta and Tobi. Sales of specialty medicines grew 5% in 4Q to $2.2 billion, driven by Copaxone and Treanda. Copaxone revenues were up 21% in 4Q to $1.1 billion. OTC revenues grew 10% in 4Q to $529 million. For FY13, generic revenues fell 5% to $9.9 billion and specialty medicines grew 3% to $8.4 billion. The drop in generic revenues is largely attributable to the loss of royalties for generic Lipitor, as well as the loss in exclusivity for generic Lexapro and Actos/Actoplus met. Copaxone revenues for FY were up 8% to $4.3 billion, while Treanda sales rose 3% to $709 million.

Related Contract Manufacturing:

blog comments powered by Disqus
  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • The Search &  Rescue Mission for Data Integrity

    The Search & Rescue Mission for Data Integrity

    Mike Jovanis, Vice President of Vault QualityDocs, Veeva Systems||October 11, 2016
    Cloud technology is essential for success